Deregulating fibroblast growth factor receptor (FGFR) signaling is a promising strategy for cancer therapy. Herein, we report the discovery of compound 5 (TAS-120, futibatinib), a potent and selective covalent inhibitor of FGFR1-4, starting from a unique dual inhibitor of mutant epidermal growth factor receptor and FGFR (compound 1). Compound 5 inhibited all four families of FGFRs in the single-digit nanomolar range and showed high selectivity for over 387 kinases. Binding site analysis revealed that compound 5 covalently bound to the cysteine 491 highly flexible glycine-rich loop region of the FGFR2 adenosine triphosphate pocket. Futibatinib is currently in Phase I-III trials for patients with oncogenically driven FGFR genomic aberrations. In September 2022, the U.S. Food & Drug Administration granted accelerated approval for futibatinib in the treatment of previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
1 January 2008 in Journal für die reine und angewandte Mathematik (Crelles Journal)
The basic model for incompressible two-phase flows with phase transitions is derived from basic principles and shown to be thermodynamically consistent in the sense that the total energy is conserved and the total entropy is nondecreasing. The local well-posedness of such problems is proved by means of the technique of maximal $L_p$-regularity in the case of equal densities. This way we obtain a local semiflow on a well-defined nonlinear state manifold. The equilibria of the system in absence of external forces are identified and it is shown that the negative total entropy is a strict Ljapunov functional for the system. If a solution does not develop singularities, it is proved that it exists globally in time, its orbit is relatively compact, and its limit set is nonempty and contained in the set of equilibria.